Cargando…

Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam

PURPOSE: Preference-based measures are required to measure the impact of interventions for cost-effectiveness analysis. This study assessed the psychometric performance of the EQ-5D-3L in adults with uncontrolled focal (partial-onset) seizures. METHODS: Data from three Phase III studies of an antiep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mukuria, Clara, Young, Tracey, Keetharuth, Anju, Borghs, Simon, Brazier, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309305/ https://www.ncbi.nlm.nih.gov/pubmed/28004320 http://dx.doi.org/10.1007/s11136-016-1483-3

Ejemplares similares

Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures
por: Lattanzi, Simona, et al.
Publicado: (2022)

Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland
por: Väätäinen, Saku, et al.
Publicado: (2019)

Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2022)

Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures
por: Chung, Steve S., et al.
Publicado: (2020)

Brivaracetam: a novel antiepileptic drug for focal-onset seizures
por: Stephen, Linda J., et al.
Publicado: (2017)

Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials
por: Ryvlin, Philippe, et al.
Publicado: (2022)

Comparison of Modes of Administration and Alternative Formats for Eliciting Societal Preferences for Burden of Illness
por: Rowen, Donna, et al.
Publicado: (2015)

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2021)

Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2021)

Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures
por: Farkas, Viktor, et al.
Publicado: (2019)

Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?
por: Swallow, Elyse, et al.
Publicado: (2017)

Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures
por: Mumoli, Laura, et al.
Publicado: (2015)

Extrapolation of a Brivaracetam Exposure–Response Model from Adults to Children with Focal Seizures
por: Schoemaker, Rik, et al.
Publicado: (2017)

Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures [Corrigendum]
Publicado: (2015)

Selecting Bolt-on Dimensions for the EQ-5D: Testing the Impact of Hearing, Sleep, Cognition, Energy, and Relationships on Preferences Using Pairwise Choices
por: Finch, Aureliano Paolo, et al.
Publicado: (2020)

Mapping Functions in Health-Related Quality of Life: Mapping from Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L
por: Young, Tracey A., et al.
Publicado: (2015)

Cost-effectiveness of perampanel as an adjunctive treatment for uncontrolled focal seizures in pediatric patients: a Chinese perspective
por: Hu, Yani, et al.
Publicado: (2022)

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study
por: Lattanzi, Simona, et al.
Publicado: (2022)

Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open‐label safety study
por: Sperling, Michael R., et al.
Publicado: (2020)

Time course of 75%–100% efficacy response of adjunctive brivaracetam
por: Klein, Pavel, et al.
Publicado: (2020)

Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures
por: Klein, Pavel, et al.
Publicado: (2022)

Long‐term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11‐year, open‐label, follow‐up trial
por: O’Brien, Terence J., et al.
Publicado: (2020)

Long‐term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open‐label extension of a randomized clinical study
por: French, Jacqueline A., et al.
Publicado: (2021)

Clinical utility of implantable neurostimulation devices as adjunctive treatment of uncontrolled seizures
por: Cox, Joanna H, et al.
Publicado: (2014)

Convergent validity of EQ-5D with core outcomes in dementia: a systematic review
por: Hussain, Hannah, et al.
Publicado: (2022)

The role of patient and public involvement and engagement (PPIE) within the development of the EQ Health and Wellbeing (EQ-HWB)
por: Carlton, Jill, et al.
Publicado: (2022)

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial
por: Sperling, Michael R, et al.
Publicado: (2015)

Clinical and Electroencephalography Assessment of the Effects of Brivaracetam in the Treatment of Drug-Resistant Focal Epilepsy
por: Savastano, Ersilia, et al.
Publicado: (2021)

Assessing the psychometric performance of EQ-5D-5L in dementia: a systematic review
por: Keetharuth, Anju D., et al.
Publicado: (2022)

Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies
por: Ben-Menachem, Elinor, et al.
Publicado: (2016)

Intravenous Brivaracetam in the Management of Acute Seizures in the Hospital Setting: A Scoping Review
por: Lee, Kiwon, et al.
Publicado: (2022)

Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial
por: Liu, Edwin, et al.
Publicado: (2019)

Critical Appraisal of Cenobamate as Adjunctive Treatment of Focal Seizures in Adults
por: Zaccara, Gaetano, et al.
Publicado: (2021)

Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of Phase II and Phase III double‐blind and open‐label extension studies in India
por: Mehndiratta, Man M., et al.
Publicado: (2021)

Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes
por: French, Jacqueline, et al.
Publicado: (2016)

Brivaracetam in treating epileptic encephalopathy and refractory focal epilepsies in patients under 14 years of age
por: RUSSO, Angelo, et al.
Publicado: (2021)

Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open‐label study
por: Sperling, Michael R., et al.
Publicado: (2021)

Clinical and Economic Outcomes of Intravenous Brivaracetam Compared With Levetiracetam for the Treatment of Seizures in United States Hospitals
por: Beaty, Silky, et al.
Publicado: (2021)

Acute and long‐term effects of brivaracetam and brivaracetam–diazepam combinations in an experimental model of status epilepticus
por: Niquet, Jerome, et al.
Publicado: (2017)

Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches
por: Acaster, Sarah, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_slqu3hjj2qo5htfc94lq4ff1co